Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1008-1013. doi: 10.1051/medsci/2019200. Epub 2020 Jan 6.

[Monoclonal antibodies in infectious diseases: new partners in the therapeutic arsenal].

[Article in French; Abstract available in French from the publisher]

Author information

1
CHU de Tours, Parasitologie-Mycologie-Médecine tropicale, 37044 Tours, France - Université de Tours, Inserm U1100, Centre d'étude des pathologies respiratoires, Faculté de médecine, 37032 Tours, France.
2
Institut de génétique moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France - IRMB, Univ Montpellier, Inserm, CNRS, Montpellier, France.

Abstract

in English, French

Development of therapeutic antibodies for treating infectious diseases is more recent than for cancer and inflammatory diseases. To date, seven antibodies have been approved worldwide and only five in France. Medical indications are so far limited to the prophylaxis of bronchiolitis caused by respiratory syncytial virus (RSV), treatment of multidrug-resistant HIV disease, exposure to rabies and anthrax pulmonary disease, prevention of diarrhea recurrence due to Clostridium difficile, and atypical hemolytic uremic syndrome caused by Escherichia coli. In a near future, new technologies would allow accelerating the development of anti-infectious monoclonal antibodies to improve the anti-bacterial and anti-viral therapeutic arsenal.

PMID:
31903909
DOI:
10.1051/medsci/2019200

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center